Cabiralizumab Biosimilar - Research Grade

Human

CSF1R

>1mg/ml

IgG4 - kappa

CHO Cells

Axatilimab Biosimilar - Research Grade (ICH5366), Emactuzumab Biosimilar - Research Grade (ICH5518)

https://www.imgt.org/mAb-DB/

ICH3002

P07333

1436

Blue ice

This product (ICH5419) is a research-grade biosimilar of Cabiralizumab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not a clinical drug and is not intended for diagnostic or therapeutic application. The molecule is built around the target antigen of the originator, human CSF1R (colony-stimulating factor 1 receptor, UniProt P07333), and is produced as a humanized IgG4-kappa immunoglobulin matching the format of the reference product. Cabiralizumab is an antagonistic anti-CSF1R antibody that has been investigated in oncology, frequently in combination with checkpoint blockade, on the rationale that blocking CSF1R signaling reprograms or depletes tumor-associated macrophages and relieves myeloid-driven immune suppression. As a biosimilar reagent, this product is intended to serve as a consistent, well-characterized tool for functional and in-vitro studies of CSF1R engagement rather than as the clinical agent itself. It is offered at research grade with low endotoxin and is available in bulk milligram-to-gram quantities to support binding, blocking, and control-arm experiments where a defined anti-CSF1R analog is needed. CSF1R (colony-stimulating factor 1 receptor; also known as CD115, c-FMS, or M-CSF-R; UniProt P07333) is a single-pass type I transmembrane receptor tyrosine kinase of the class III (PDGFR) family. It is engaged by two ligands, CSF1 (M-CSF) and IL-34, whose binding drives receptor dimerization, autophosphorylation, and downstream signaling through pathways including PI3K-AKT and MAPK. CSF1R signaling is central to the development, survival, proliferation, and functional polarization of the mononuclear phagocyte lineage, including monocytes, tissue macrophages, microglia, and osteoclasts. In tumors, the CSF1-CSF1R axis supports recruitment and maintenance of immunosuppressive tumor-associated macrophages, making receptor blockade an attractive strategy to remodel the myeloid compartment of the tumor microenvironment and enhance anti-tumor immunity.

CSF-1 receptor, M-CSF-R, Proto-oncogene c-Fms, Macrophage colony-stimulating factor 1 receptor, FMS

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Cabiralizumab (anti-CSF1R) Biosimilar

Q: Is the Cabiralizumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Cabiralizumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Cabiralizumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Cabiralizumab that binds CSF1R; for research use only.